At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 302 enrolled
Drug / intervention
Dutasteride +1 moredrug
Likely dose
Dutasteride 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management
In Brief
A Phase 4 clinical trial evaluating Dutasteride and Matching placebo for Neoplasms, Prostate. Completed, enrolled 302 participants across 82 sites in 2 countries.
Detailed Summary
The purpose of this study is to examine the effect of dutasteride on the inhibition of low-risk, localized prostate cancer progression in men who would otherwise receive no active therapy (expectant management).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Prostate
CountriesCanada, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedAug 2006
Primary CompletionMar 2010
Study CompletionJul 2010
TodayJul 2026
First PostedAug 15, 2006
Enrollment StartJul 1, 2006
Primary CompletionMar 1, 2010
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 19.9 years ago
Interventions
Dutasteridedrug
Dutasteride 0.5mg
Matching placebodrug
Matching placebo